Healthcare Industry News: duodenal ulcer
News Release - October 8, 2006
Eisai Receives Summary Judgment Motion Decisions in U.S. Legal Action Over Aciphex(R) ANDA FilingsTEANECK, N.J., Oct. 8 (HSMN NewsFeed) -- Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO: Haruo Naito) and Eisai Inc. (Headquarters: New Jersey, Chairman and CEO: Hajime Shimizu) today announce that they received court decisions on ANDA-related summary judgment motions for Aciphex® (Active Ingredient Name: rabeprazole sodium, Product Name in Japan: Pariet®) on October 6, 2006 (U.S. Eastern time).
Aciphex® has been shown to have a rapid onset of action and a reliable inhibitory effect on acid secretion related to duodenal ulcers and gastroesophageal reflux disease, which are confirmed in clinical studies. Aciphex® was launched in the U.S. in 1999 and is currently marketed worldwide.
Aciphex® has a well-established safety profile. The most common side effect possibly related to Aciphex® is headache. Symptom relief does not rule out other serious stomach conditions. Patients on Warfarin (such as Coumadin®) may need to be monitored more closely by their doctor. For more information, visit www.aciphex.com or www.eisai.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.